Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Selinexor Plus Ruxolitinib May Improve Overall Survival in Patients With MF

Nurses Are Key to Identifying Hidden Burdens of Myeloproliferative Neoplasms

Validity of The Danish National Chronic Myeloid Neoplasia Registry

Incyte stock (US45337C1027): Is Jakafi's dominance now the key to sustained biotech growth?

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

When Should You Employ Transplantation in Myelofibrosis Therapy?

Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans ...

Imetelstat anchors growth in low-risk MDS, with pivotal MF trial data expected in H2 2024

Beacon Harbor Wealth Advisors Boosts Incyte Corporation Holdings

Clinical outcomes in triple-negative myeloproliferative neoplasms with extreme thrombocytosis

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation ...

A humanized ossicle model of myelofibrosis reveals THPO-driven fibrosis, osteosclerosis ...

Researchers Aim to Expand Primary Myelofibrosis Treatment Options

Primary Myelofibrosis Pipeline 2026: Therapies Under Investigation, Clinical Trials ...

Race Across the World's Mark shares extraordinary connection with Greek stranger

Pacritinib Proves Feasible as Pre-Transplant Bridge Therapy in Myelofibrosis

Echocardiographic High-Output Heart Failure Predicts Worse Survival in Myelofibrosis

Tyrosine Kinase JAK Inhibitors Market Size & Share Trends, 2035

A paradigm shift in the treatment of patients with polycythemia vera . The initial early use of ...

Log in to enable infinite scrolling